Cytosolic DNA sensor cGAS plays an essential pathogenetic role in pressure overload-induced heart failure

Dan Hu1, Yu-Xia Cui1, Man-Yan Wu1

  • 1Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Center for Cardiovascular Translational Research, Peking University People's Hospital, Beijing, China.

Insights

Cyclic GMP-AMP synthase (cGAS) activation drives heart failure by promoting inflammation and cardiac remodeling. Inhibiting cGAS protects against pressure overload-induced heart failure, suggesting a new therapeutic target.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Inflammation contributes to left ventricular (LV) remodeling and dysfunction in heart failure (HF).
  • Cyclic GMP-AMP synthase (cGAS) is a cytosolic DNA sensor crucial for innate immunity via the STING-IRFs-type I IFN pathway.
  • The role of cGAS in pressure overload-induced HF remains largely unknown.

Purpose of the Study:

  • To investigate the pathophysiological role of cGAS in pressure overload-induced HF.
  • To determine if inhibiting cGAS can ameliorate cardiac dysfunction and remodeling.

Main Methods:

  • Induction of HF in mice using transverse aortic constriction (TAC) or sham operation.
  • Inhibition of cardiac cGAS using adeno-associated virus 9 (AAV9).
  • Assessment of cGAS/STING pathway activation, cardiac remodeling (echocardiography, histology), LV function, and inflammatory markers.

Main Results:

  • The cGAS/STING pathway was significantly activated in the LV of TAC-induced HF mice.
  • Inhibition of cGAS improved survival, preserved LV function, and reduced cardiac hypertrophy, fibrosis, and apoptosis post-TAC.
  • Downregulation of cGAS diminished inflammatory cell infiltration and cytokine expression following TAC.

Conclusions:

  • cGAS plays a critical role in promoting pathological cardiac remodeling and dysfunction in pressure overload-induced HF.
  • Inhibition of the cGAS/STING pathway represents a potential novel therapeutic strategy for treating HF.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
277
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
330
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
583
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Global Regulatory Systems01:28

Global Regulatory Systems

Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
475